|
Showing 1 - 1 of
1 matches in All Departments
In several liver diseases, the underlying cause cannot always be
eliminated, i.e. the progression of liver disease cannot be
prevented. This is particularly true for non-responders to the
treatment of chronic hepatitis C (HCV). It is relevant for more
than 40 per cent of patients with HCV genotype 1 and up to 20 per
cent of patients with genotype 2 or 3. Several approaches are now
underway to prevent or ameliorate mechanisms of disease
progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC
has been widely used for this purpose. At present, SNMC is under
clinical evaluation in Europe.
|
You may like...
Gloria
Sam Smith
CD
R407
Discovery Miles 4 070
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.